ChromaDex Corp., a leading developer of phytochemical and botanical reference standards and analytical tools and services, today announced that the National Science Foundation has awarded the company a $500,000 phase II Small Business Innovation Research (SBIR) Grant for the company’s project called “SBIR Phase II: Microbial Production of Selected Anthocyanins.”
The grant will enable the company to continue with the commercial development of several plant-based antioxidants called anthocyanins for use in nutraceutical, food, beverage and cosmetic products.
ChromaDex will combine the grant money with its own resources to complete validation of anthocyanins using its AnthoPure™ technology to meet growing demand for natural ingredients in the market place.
Bill Spengler, president of ChromaDex, said the funding is an important step in its business strategy and that the anthocyanins have promising potential for the company.
“The development of anthocyanins through our AnthoPure technology represents the next stage in our commercialization strategy of new and novel ingredients at ChromaDex,” Spengler stated in the press release. “This follows the development of pTeroPure™ pterostilbene, which is currently undergoing clinical trials for cholesterol reduction and oxidative stress at the University of Mississippi. We believe the revenue potential for select, high purity anthocyanins will be significant, but until recently there has not been a commercially viable process by which to manufacture them.”
For more information, visit www.chromadex.com
Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net
ChromaDex Corp. (CDXC.OB) Receives $500,000 Grant to Commercialize Antioxidant Technology
QualityStocks's Blog
475 Followers
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.